Based on this rationale, the phase II RT1 trial evaluated the combination of the BTK inhibitor zanubrutinib and the PD-1 inhibitor tislelizumab in DLBCL-type RT, yielding promising results with an ORR of 58.3% and a complete response (CR) rate of 18.8% [100]. Here, BTK is linked to diffuse large B-cell lymphoma.